Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Price:
52.59
CNY
4.04%
Market Closed
Market Cap:
¥41.3B
Income Statement
Earnings Waterfall
Shenzhen New Industries Biomedical Engineering Co Ltd
Shenzhen New Industries Biomedical Engineering Co Ltd
Income Statement
Shenzhen New Industries Biomedical Engineering Co Ltd
Shenzhen New Industries Biomedical Engineering Co Ltd
Currency: CNY
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
1 570
N/A
|
2 195
+40%
|
2 439
+11%
|
2 451
+0%
|
2 519
+3%
|
2 545
+1%
|
2 756
+8%
|
2 737
-1%
|
2 948
+8%
|
3 047
+3%
|
3 180
+4%
|
3 495
+10%
|
3 658
+5%
|
3 930
+7%
|
4 075
+4%
|
4 275
+5%
|
4 436
+4%
|
4 535
+2%
|
4 639
+2%
|
4 509
-3%
|
4 549
+1%
|
|
| Gross Profit | ||||||||||||||||||||||
| Cost of Revenue |
(350)
|
(501)
|
(578)
|
(669)
|
(729)
|
(734)
|
(798)
|
(825)
|
(883)
|
(906)
|
(986)
|
(1 016)
|
(1 023)
|
(1 062)
|
(1 071)
|
(1 150)
|
(1 221)
|
(1 267)
|
(1 379)
|
(1 379)
|
(1 436)
|
|
| Gross Profit |
1 220
N/A
|
1 694
+39%
|
1 860
+10%
|
1 781
-4%
|
1 789
+0%
|
1 811
+1%
|
1 957
+8%
|
1 911
-2%
|
2 065
+8%
|
2 141
+4%
|
2 194
+2%
|
2 479
+13%
|
2 635
+6%
|
2 867
+9%
|
3 004
+5%
|
3 126
+4%
|
3 214
+3%
|
3 269
+2%
|
3 259
0%
|
3 130
-4%
|
3 113
-1%
|
|
| Operating Income | ||||||||||||||||||||||
| Operating Expenses |
(445)
|
(656)
|
(717)
|
(753)
|
(766)
|
(718)
|
(696)
|
(724)
|
(774)
|
(789)
|
(804)
|
(911)
|
(943)
|
(1 097)
|
(1 159)
|
(1 141)
|
(1 199)
|
(1 313)
|
(1 288)
|
(1 352)
|
(1 384)
|
|
| Selling, General & Administrative |
(365)
|
(483)
|
(597)
|
(634)
|
(623)
|
(493)
|
(505)
|
(495)
|
(507)
|
(433)
|
(490)
|
(583)
|
(609)
|
(686)
|
(796)
|
(762)
|
(796)
|
(793)
|
(869)
|
(905)
|
(925)
|
|
| Research & Development |
(114)
|
(136)
|
(163)
|
(155)
|
(180)
|
(198)
|
(233)
|
(262)
|
(296)
|
(297)
|
(342)
|
(357)
|
(366)
|
(336)
|
(384)
|
(398)
|
(422)
|
(410)
|
(454)
|
(486)
|
(498)
|
|
| Depreciation & Amortization |
0
|
(51)
|
0
|
0
|
0
|
(64)
|
0
|
0
|
0
|
(79)
|
0
|
0
|
0
|
(108)
|
0
|
0
|
0
|
(134)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
34
|
14
|
44
|
37
|
36
|
37
|
42
|
34
|
29
|
20
|
28
|
29
|
31
|
32
|
21
|
19
|
19
|
24
|
35
|
39
|
40
|
|
| Operating Income |
775
N/A
|
1 038
+34%
|
1 143
+10%
|
1 029
-10%
|
1 023
-1%
|
1 093
+7%
|
1 261
+15%
|
1 187
-6%
|
1 291
+9%
|
1 352
+5%
|
1 390
+3%
|
1 569
+13%
|
1 692
+8%
|
1 770
+5%
|
1 845
+4%
|
1 984
+8%
|
2 015
+2%
|
1 956
-3%
|
1 971
+1%
|
1 778
-10%
|
1 729
-3%
|
|
| Pre-Tax Income | ||||||||||||||||||||||
| Interest Income Expense |
37
|
61
|
31
|
12
|
34
|
44
|
32
|
107
|
135
|
151
|
161
|
147
|
118
|
126
|
132
|
104
|
115
|
155
|
150
|
152
|
150
|
|
| Non-Reccuring Items |
0
|
(1)
|
0
|
0
|
0
|
(2)
|
0
|
1
|
1
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(1)
|
(1)
|
(2)
|
(4)
|
(3)
|
(0)
|
(2)
|
(1)
|
(1)
|
(1)
|
(2)
|
(3)
|
(3)
|
(1)
|
(2)
|
(19)
|
(19)
|
(18)
|
(19)
|
(2)
|
(4)
|
|
| Pre-Tax Income |
812
N/A
|
1 097
+35%
|
1 173
+7%
|
1 037
-12%
|
1 055
+2%
|
1 136
+8%
|
1 290
+14%
|
1 295
+0%
|
1 426
+10%
|
1 501
+5%
|
1 549
+3%
|
1 713
+11%
|
1 807
+6%
|
1 893
+5%
|
1 974
+4%
|
2 069
+5%
|
2 111
+2%
|
2 093
-1%
|
2 103
+0%
|
1 928
-8%
|
1 876
-3%
|
|
| Net Income | ||||||||||||||||||||||
| Tax Provision |
(113)
|
(158)
|
(177)
|
(145)
|
(148)
|
(162)
|
(176)
|
(180)
|
(193)
|
(173)
|
(174)
|
(204)
|
(217)
|
(239)
|
(249)
|
(262)
|
(261)
|
(265)
|
(263)
|
(232)
|
(226)
|
|
| Income from Continuing Operations |
698
|
939
|
997
|
892
|
906
|
974
|
1 114
|
1 115
|
1 233
|
1 328
|
1 375
|
1 508
|
1 590
|
1 654
|
1 725
|
1 807
|
1 851
|
1 828
|
1 840
|
1 696
|
1 650
|
|
| Net Income (Common) |
698
N/A
|
939
+34%
|
997
+6%
|
892
-10%
|
906
+2%
|
974
+7%
|
1 114
+14%
|
1 115
+0%
|
1 233
+11%
|
1 328
+8%
|
1 375
+4%
|
1 508
+10%
|
1 590
+5%
|
1 654
+4%
|
1 725
+4%
|
1 807
+5%
|
1 851
+2%
|
1 828
-1%
|
1 840
+1%
|
1 696
-8%
|
1 650
-3%
|
|
| EPS (Diluted) |
0.9
N/A
|
1.25
+39%
|
1.26
+1%
|
1.13
-10%
|
1.15
+2%
|
1.24
+8%
|
1.41
+14%
|
1.42
+1%
|
1.57
+11%
|
1.69
+8%
|
1.75
+4%
|
1.92
+10%
|
2.02
+5%
|
2.1
+4%
|
2.19
+4%
|
2.3
+5%
|
2.35
+2%
|
2.33
-1%
|
2.34
+0%
|
2.16
-8%
|
2.1
-3%
|
|
Switch to:
Switch to:
See Also
Discover More
